Tag Archives: hypertension

The level of nitric oxide and arginase activity in patients with arterial hypertension and diabetes mellitus during COVID-19

O. Y. Sklyarova1, S. R. Mahiiovych2, N. V. Denysenko3,
L. I. Kobylinska3*, Y. Y. Sklyarov2

1Department of Family Medicine FPGE, Danylo Halytsky Lviv National Medical University, Ukraine;
2Department of Therapy No 1 and Medical Diagnostics FPGE, Danylo Halytsky Lviv National Medical University, Ukraine;
3Department of Biological Chemistry, Danylo Halytsky Lviv National Medical University, Ukraine;
*e-mail: lesyaivanivna.biochemistry@gmail.com

Received: 28 September 2022; Revised: 06 November 2022;
Accepted: 11 November 2022; Available on-line: 19 December 2022

The aim of this study was to assess the level of nitric oxide production and arginase activity in patients with arterial hypertension and type II diabetes mellitus during infection with SARS-CoV-2. The study groups included patients with arterial hypertension, patients with arterial hypertension combined with a severe course of COVID-19 and patients who, in addition to arterial hypertension and COVID-19, were suffering from type II diabetes mellitus. The volunteers without any clinical signs of diseases and normal blood pressure formed the control group. It has been established that arterial hypertension, combined with COVID-19 occurs along with reduced L-arginine, nitric oxide, superoxide dismutase activity and increased arginase activity. At the same time, the presence of arterial hypertension in patients with diabetes and coronavirus disease is accompanied by a decline in the content of L-arginine and arginase activity. Our study’s results may help scientists find new pharmacological targets in the future treatment of coronavirus disease and comorbid disorders.

Practical development of laboratory of biologics technology of the Palladin Institute of Biochemistry of NAS of Ukraine for the period 1991-2010

G. G. Lugovska, R. P. Vynogradova, N. E. Lugovska,
I. G. Chernysh, S. P. Yurasova, V. M. Danilova

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
e-mail: tto@biochem.kiev.ua

The paper presents the results of inventive activity of the Laboratory of Biologics Technology of the Palladin Institute of Biochemistry, NAS of Ukraine, under the leadership of Z.M.Datsenko, Cand.Sc. (Biol.), during 1991-2010. The laboratory researchers have developed new technologies for production of medicines of lipid-protein nature, which are based on endogenous complexes of biologically active substances included in the composition of biomembranes of different origin. The researchers have created new technologies for drug PANTOCRINE (for injections and oral administration) from antlers of deers and horns of farm animals that have significantly higher biological activity compared with the commercial drug.  They have also created new biologically active drugs from antlers with a specific action: HIPPOCAMP, reducing blood pressure in various forms of hypertension, and PANTERON – biological regulator of synthesis of steroid hormones. Further the researchers have developed technologies for obtaining biologically active complexes of various specific action from marine organisms (calamari, clams mussels, shellfish): CALMOFIL and MOLUFIL, therapeutic agents for replacement therapy of surfactant system of the lungs; FILOMEK, the agent for prophylaxis and treatment of a human reproductive system disorders; MOLUSTERON, the glicolipopeptide complex, three individual physiologically active compositions being differentially obtained from the latter: lipopeptide composition – for treatment of hypertension, nucleopeptide one – for treatment of hormonal disorders, and phospholipid – for treatment of lung diseases under the surfactant shortage.